Obermatt
See Similar Stocks →

Chong Kun Dang

KSC:185750 · KR7185750007
PharmaceuticalsSmall

360

55
Medium confidence — indicative
EV / EBIT46
Price / Owner Earnings90
Owner Earnings Yield1
Dividend Yield57
Price/Sales89
EV / Gross Profit81
Price/Book71
Return on Capital65
Cash Return on Capital35
Return on Equity62
EBIT Margin50
Gross Profitability61
Cash Conversion51
Accruals13
Owner Earnings Margin34
Sales growth79
Profit Growth36
Long-Term EPS Growth57
Owner Earnings Growth7
Reinvestment94
Price momentum48
Debt load54
Refinancing68
Debt Payback1
Liquidity67
Analyst ratings76
Opinion Changes50
Price Target Upside49
Market mood57
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Chong Kun Dang clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees73
Websiteckdpharm.com
ISINKR7185750007
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
DiabetesCardiovascularChronic DiseasesNutraceuticalInternal DiseasesBiotechnologyPharmaceutical

Description

Analysis

Middle-of-the-road

Chong Kun Dang Pharmaceutical Corp. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
96
2023202420252026

All-time high

96

Jun 2026

All-time low

41

Jan 2023

Average rank

71

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
89
84
70
87
Price/Earnings
41
51
40
51
Price/Book
71
43
29
39
Dividend Yield
57
34
31
32
Value (overall)
75
46
34
51

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Chong Kun Dang with its peers
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Sumitomo Dainippon Pharma
TYO:4506
79
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Dongwha Pharm
KSC:000020
44
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Lotus Pharmaceutical
TAI:1795
19
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →